Ece Harman HARMAN, Yavuz Dodurga, Gulsah Gundogdu, Ceylan AYADA, Gulten Erken, Vural Kucukatay, Cigir Biray AVCİ, Osman Genc

Copeptin: May it be a novel biomarker for insulin theraphy in diabetes? An animal study

Copeptin is a marker about prognosis of acute illnesses, generally. It may be also an indicator associated with treatment of chronic diseases. We aimed to evaluate copeptin levels in rat models with stress, diabetes, diabetes+insulin. Healthy male Wistar rats, about 3 months old, weighing 200 "250 g, were obtained from University Animal House. They were housed in small cages at standard conditions (24 ± 2°C and 50 ± 5% humidity) with a 12 h light/dark cycle and were fed ad libitum with standard rat chow and tap water. Rats were divided into 4 groups: 8 control (C), 8 diabetic (D), 8 diabetic+insulin (DI) and 8 stress (S) rats. Quantitative measurement of Copeptin was performed using the ELISA method (Uscn Life Sciences, USA), according to the manufactur ers instructions. Copeptin level was statistically significant decreased in D+I groups. There was no difference in copeptin level between the S, D, and C groups. Copeptin may be considered as a new tool for the comparison of the efficiencies of new therapeutic modalities in diabetes.

Anahtar Kelimeler:

Copeptin, insulin, diabetes

Copeptin: May it be a novel biomarker for insulin theraphy in diabetes? An animal study

Keywords:

Copeptin, insulin, diabetes,

PDF

___

Holwerda DA. A glycopeptide from the posterior lobe of pig pituitaries. Isolation and characterization. Eur J Biochem. 1972;28(3):334–9.
Struck J, Morgenthaler NG, Bergmann A. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides. 2005;26(12):2500–4.
Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006; 52(1):112–9.
KatanM, Müler B, Crain MC. Copeptin: A new and promising diagnostic and prognostic marker. Critical Care. 2008;12(2):117-8.
Katan M, Morgenthaler N, Widmer I, Puder JJ, Konig C, Muller B, Christ-Crain M. Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol Lett. 2008;29(3):341-6.
Morgenthaler NG, Struck J, Jochberger S, Dunser MW. Copeptin: Clinical use of a new biomarker. Trends in endocrinology and metabolism: TEM. 2008,19(2):43-9. Katan M, Fluri F, Morgenthaler NG, Schuetz P, Zweifel C, Bingisser R, MüllerK, Meckel S, Gass A, Kappos L, Steck AJ, Engelter ST, Müller B, Christ-Crain M. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol. 2009:66(6):799-808.
Antoni FA. Vasopressinergic control of pituitary adrenocorticotropin secretioncomes of age. Front Neuroendocrinol. 1993;14(2):76-122.
Keppens S, de Wulf H. The nature of the hepatic receptors involved in vasopressininduced glycogenolysis. Biochim Biophys Acta. 1979;588(1):63-9.
Abu-Basha EA, Yibchok-Anun S, Hsu WH. Glucose dependency of argininevasopressin-induced insulin and glucagon release from the perfused rat pancreas.Metabolism. 2002;51(9):1184-90.
Struck J, Morgenthaler NG, Bergmann A. Copeptin, a stable peptide derived fromthe vasopressin precursor, is elevated in serum of sepsis patients. Peptides. 2005;26(12):2500-4.
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26(Suppl. 1):S5-20.
Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115(5):1111-9.
Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, CreagerMA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J,Vogel R. International Brachial Artery Reactivity Task Force. Guidelines for theultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the international brachial artery reactivity task force. J Am Coll Cardiol. 2002;39:257-65.
Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB, Sr, Perez A, Provost JC, Haffner SM. Effect of pioglitazone compared with glimepirideon carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 2006;296(21):2572-81.
Musi N, Fujii N, Hirshman MF, Ekberg I, Fröberg S, Ljungqvist O, Thorell A, Goodyear LJ. AMP-activated protein kinase (AMPK) is activated in muscle ofsubjects with type 2 diabetes during exercise. Diabetes. 2001;50(5):921-7.
Joya-Galeana J, Fernandez M, Cervera A, Reyna S, Ghosh S, Triplitt C,. Musi N, DeFronzo RA, Cersosimo E. Effects of insulin and oral anti-diabetic agents onglucose metabolism, vascular dysfunction and skeletal muscle inflammation in type2 diabetic subjects. Diabetes Metab Res Rev. 2011;27(4):373-82.
Enhörning S, Wang TJ, Nilsson PM, Almgren P, Hedblad B, Berglund G, Struck J, Morgenthaler NG, Bergmann A, Lindholm E, Groop L, Lyssenko V, Orho-Melander M, Newton-Cheh C, Melander O. Plasma copeptin and the risk of diabetes mellitus. Circulation. 2010;121(19):2102-8.
Enhörning S, Bankir L, Bouby N, Struck J, Hedblad B, Persson M, Morgenthaler NG, Nilsson PM, Melander O. Copeptin, a marker of vasopressin, in abdominalobesity, diabetes and microalbuminuria: the prospective Malmö Diet and CancerStudy cardiovascular cohort. Int J Obes (Lond). 2012 May 22. doi:10.1038/ijo.2012.88. [Epub ahead of print] PubMed PMID: 22614056.
Bardoux P, Bichet DG, Martin H, Gallois Y, Marre M, Arthus MF, Lonergan M,Ruel N, Bouby N, Bankir L. Vasopressin increases urinary albumin excretion inrats and humans: involvement of V2 receptors and the renin-angiotensin system.Nephrol Dial Transplant. 2003;18(3):497-506.
Bardoux P, Martin H, Ahloulay M, Schmitt F, Bouby N, Trinh-Trang-Tan MM, Bankir L. Vasopressin contributes to hyperfiltration, albuminuria, and renalhypertrophy in diabetes mellitus: study in vasopressin-deficient Brattlebororats. Proc Natl Acad Sci U S A. 1999;96(18):10397-402.
Enhörning S, Struck J, Wirfält E, Hedblad B, Morgenthaler NG, Melander O.Plasma copeptin, a unifying factor behind the metabolic syndrome. J Clin Endocrinol Metab. 2011;96(7):E1065-72.
Fenske W, Wanner C, Allolio B, Drechsler C, Blouin K, Lilienthal J, Krane V; German Diabetes, Dialysis Study Investigators. Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus. J Am Soc Nephrol. 2011;22(4):782-90.